1. Home
  2. CRF vs IVA Comparison

CRF vs IVA Comparison

Compare CRF & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cornerstone Total Return Fund Inc. (The)

CRF

Cornerstone Total Return Fund Inc. (The)

N/A

Current Price

$6.10

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

N/A

Current Price

$3.82

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CRF
IVA
Founded
N/A
2011
Country
United States
France
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
CRF
IVA
Price
$6.10
$3.82
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$16.20
AVG Volume (30 Days)
1.6M
1.0M
Earning Date
01-01-0001
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$751.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.30
$3.35
52 Week High
$8.25
$7.98

Technical Indicators

Market Signals
Indicator
CRF
IVA
Relative Strength Index (RSI) 26.31 30.07
Support Level N/A $3.35
Resistance Level $7.31 $4.78
Average True Range (ATR) 0.08 0.27
MACD -0.00 -0.11
Stochastic Oscillator 21.28 10.14

Price Performance

Historical Comparison
CRF
IVA

About CRF Cornerstone Total Return Fund Inc. (The)

Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology, Health Care, Financials, Communication Services, Consumer Discretionary, Industrials, Exchange-Traded Funds, Utilities, Energy, Real Estate, and others.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.

Share on Social Networks: